PLC - AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer | Benzinga
Monday, AstraZeneca Plc (NASDAQ:PLC) released latest analysis of the results from the DUO-E Phase 3 trial of Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) in mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone.
The data demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone.
A post-hoc exploratory subgroup analysis assessed patients by mismatch repair (MMR) status, a biomarker of interest in endometrial cancer.
In this analysis, the median duration of response (DoR) in pMMR patients ...